Product Information

ACETAMINOPHEN 650 MG SUPPOS is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.3451 per EA under NDC 45802073000. Its NADAC has been published 481 times since Sep 6, 2017.

FDA first approved this application on Dec 1, 1986.

The High Outlier badge above means this manufacturer's average price in the Acetaminophen market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ACETAMINOPHEN 650 MG SUPPOS

Acetaminophen
$0.3451per EA
High Outlier
OTC

Strength

650 mg/1

NDC

45802073000

Classification

Generic

Dosage Form

SUPPOSITORY

Route

RECTAL

Effective Date

11/18/2026

Active Ingredients

ACETAMINOPHEN

Approval Type

Generic (ANDA)

FDA Application

ANDA070608

FDA Approved

12/1/1986

On Market Since

10/28/2010

Price Statistics

The NADAC for ACETAMINOPHEN 650 MG SUPPOS has been published 481 times since Sep 6, 2017, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$0.3451 per EA
All-time high$0.3731 (Mar 14, 2018)
All-time low$0.2796 (Dec 20, 2017)
52-week high$0.3494
52-week low$0.3389
Median price$0.3391
Average price$0.3357
Largest weekly change+28.1% (Jan 17, 2018)
Weeks tracked481
Tracking sinceSep 6, 2017

Price History

1W

-0.3%

1M

-1.2%

3M

-0.4%

6M

+0.8%

1Y

+1.8%

3Y

+2.2%

5Y

+0.8%

All

-0.1%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Related Drugs

Same classification

No related drugs found.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ACETAMINOPHEN 650 MG SUPPOS?

The current National Average Drug Acquisition Cost (NADAC) for ACETAMINOPHEN 650 MG SUPPOS, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.3451 per EA (NDC 45802073000), effective Nov 18, 2026.

How has the price of ACETAMINOPHEN 650 MG SUPPOS changed over time?

Over the history we have for it, the NADAC for ACETAMINOPHEN 650 MG SUPPOS has held within roughly two percent of its current level. It has been tracked across 481 weekly CMS publications since Sep 6, 2017.

What are the highest and lowest recorded NADAC prices for ACETAMINOPHEN 650 MG SUPPOS?

Since Sep 6, 2017, the NADAC for ACETAMINOPHEN 650 MG SUPPOS has ranged from a low of $0.2796 (Dec 20, 2017) to a high of $0.3731 (Mar 14, 2018), with a median of $0.3391 per EA.

Are there cheaper alternatives to ACETAMINOPHEN 650 MG SUPPOS?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ACETAMINOPHEN 650 MG SUPPOS in a comparable dosage form, but none are currently priced below it.

Who manufactures ACETAMINOPHEN 650 MG SUPPOS?

ACETAMINOPHEN 650 MG SUPPOS (NDC 45802073000) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.